Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi, Eisai Look Beyond Japan To Expanded Markets In Southeast Asia (Japan)

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo and Eisai are reaching beyond their Japan bases into other Asian markets to seek faster growth than they are seeing at home. Daiichi is looking to India as a good market for some of its flagship products, beginning in the spring, and is hiring a 100-person sales force, but Taiwan and other Asian markets also are in Daiichi plans. Eisai plans drug trials in China where it hopes to tap into a huge market, beginning with one for hepatitis B. Also in Eisai plans are member countries of the Association of Southeast Asian Nations where Eisai is looking for a 20 percent annual sales increase. (Click here for more - may require a subscription

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel